Regensburger, Martin and Ip, Chi Wang and Kohl, Zacharias and Schrader, Christoph and Urban, Peter P. and Kassubek, Jan and Jost, Wolfgang H. (2023) Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations. JOURNAL OF NEURAL TRANSMISSION, 130 (6). pp. 847-861. ISSN 0300-9564, 1435-1463
Full text not available from this repository. (Request a copy)Abstract
Inhibitors of monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT) are major strategies to reduce levodopa degradation and thus to increase and prolong its effect in striatal dopaminergic neurotransmission in Parkinson's disease patients. While selegiline/rasagiline and tolcapone/entacapone have been available on the market for more than one decade, safinamide and opicapone have been approved in 2015 and 2016, respectively. Meanwhile, comprehensive data from several post-authorization studies have described the use and specific characteristics of the individual substances in clinical practice under real-life conditions. Here, we summarize current knowledge on both medication classes, with a focus on the added clinical value in Parkinson's disease. Furthermore, we outline practical considerations in the treatment of motor fluctuations and provide an outlook on ongoing studies with MAO-B and COMT inhibitors.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | O-METHYLTRANSFERASE INHIBITOR; EXPERIENCING WEARING-OFF; DELAYED-START TRIAL; MONOAMINE-OXIDASE-B; MOVEMENT-DISORDER SOCIETY; DOUBLE-BLIND; MOTOR FLUCTUATIONS; ADD-ON; PRESSOR-RESPONSE; L-DOPA; Parkinson's disease; MAO-B inhibitors; COMT inhibitors; Motor fluctuations |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 08 May 2024 10:30 |
| Last Modified: | 08 May 2024 10:30 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60276 |
Actions (login required)
 |
View Item |
